Gwen Carscadden Net Worth

The estimated Net Worth of Gwen R. Carscadden is at least $1.47 Milion dollars as of 12 January 2018. Ms. Carscadden owns over 10,000 units of Intersect ENT Inc stock worth over $391,293 and over the last 8 years she sold XENT stock worth over $0. In addition, she makes $1,082,540 as Chief People Officer at Intersect ENT Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Carscadden XENT stock SEC Form 4 insiders trading

Gwen has made over 1 trades of the Intersect ENT Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently she exercised 10,000 units of XENT stock worth $121,900 on 12 January 2018.

The largest trade she's ever made was exercising 10,000 units of Intersect ENT Inc stock on 12 January 2018 worth over $121,900. On average, Gwen trades about 833 units every 0 days since 2016. As of 12 January 2018 she still owns at least 13,856 units of Intersect ENT Inc stock.

You can see the complete history of Ms. Carscadden stock trades at the bottom of the page.

Gwen Carscadden biography

Gwen R. Carscadden is no longer serves as Chief People Officer of the Company effective 1/4/2021. She has served as our Chief People Officer since June 2016. From January 2015 to June 2016, Ms. Carscadden served as Senior Vice President of Human Resources and Facilities of CardioDx, Inc., a private cardiovascular genomic diagnostics company in California, where she was responsible for strategic human resources and facilities direction, and from August 2012 to January 2015 she served as Vice President of Human Resources and Facilities of CardioDx. From November 2010 to August 2012, she provided consulting services to various life sciences companies. From January 2008 to October 2010, Ms. Carscadden served as Vice President of Human Resources of Facet Biotech Corporation, a public biotechnology spin-off from PDL BioPharma, Inc. subsequently acquired by Abbott Laboratories in April 2010.

What is the salary of Gwen Carscadden?

As the Chief People Officer of Intersect ENT Inc, the total compensation of Gwen Carscadden at Intersect ENT Inc is $1,082,540. There are 4 executives at Intersect ENT Inc getting paid more, with Thomas West having the highest compensation of $7,206,100.

How old is Gwen Carscadden?

Gwen Carscadden is 58, she's been the Chief People Officer of Intersect ENT Inc since 2016. There are 9 older and 4 younger executives at Intersect ENT Inc. The oldest executive at Intersect ENT Inc is Frederic Moll, 68, who is the Independent Director.

What's Gwen Carscadden's mailing address?

Gwen's mailing address filed with the SEC is C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK, CA, 94025.

Insiders trading at Intersect ENT Inc

Over the last 10 years, insiders at Intersect ENT Inc have traded over $22,664,783 worth of Intersect ENT Inc stock and bought 58,846 units worth $713,631 . The most active insiders traders include Rick D Anderson, Lisa D Earnhardt a W Anthony Vernon. On average, Intersect ENT Inc executives and independent directors trade stock every 18 days with the average trade being worth of $344,556. The most recent stock trade was executed by Frederic H Moll on 19 January 2021, trading 12,500 units of XENT stock currently worth $9,000.

What does Intersect ENT Inc do?

Intersect ENT is a global ear, nose and throat medical technology leader dedicated to transforming patient care. The Company's steroid releasing implants are designed to provide mechanical spacing and deliver targeted therapy to the site of disease. In addition, Intersect ENT is continuing to expand its portfolio of products based on the Company's unique localized steroid releasing technology and is committed to broadening patient access to less invasive and more cost-effective care. In October 2020, Intersect ENT acquired Fiagon AG Medical Technologies, a global leader in electromagnetic surgical navigation solutions with an expansive portfolio of ENT product offerings, including the VENSURE sinus balloon, that complement the Company's PROPEL® and SINUVA® sinus implants and extend its geographic reach.

Complete history of Ms. Carscadden stock trades at Intersect ENT Inc

Intersect ENT Inc executives and stock owners

Intersect ENT Inc executives and other stock owners filed with the SEC include:

• Thomas West,
  President, Chief Executive Officer, Director
• Kieran Gallahue,
  Non-Executive Chairman of the Board
• Richard Meier,
  Chief Financial Officer, Executive Vice President
• Christine Kowalski,
  Chief Operating Officer, Executive Vice President
• Gwen Carscadden,
  Chief People Officer
• Thomas A. West,
  Pres, CEO & Director
• Richard A. Meier,
  Exec. VP & CFO
• Cynthia Lucchese,
  Independent Director
• Dana Mead,
  Independent Director
• William Vernon,
  Independent Director
• Teresa Kline,
  Independent Director
• Frederic Moll,
  Independent Director
• Patrick A. Broderick,
  Exec. VP, Gen. Counsel & Corp. Sec.
• Reyna M. Fernandez,
  Chief Human Resource Officer
• Drake R. Parker,
  Advisor of Strategic Initiatives
• Jeryl L Hilleman,
  Chief Financial Officer
• Lisa D Earnhardt,
  
• Casey M Tansey,
  Director
• Amy Wolbeck,
  See Remarks
• Susan P Stimson,
  Vice President, Marketing
• Richard E Kaufman,
  See Remarks
• Drake R. Parker,
  Chief Business Officer
• David Aaron Lehman,
  EVP & General Counsel
• Neil A Hattangadi,
  
• Robert H Jr Binney,
  Chief Commercial Officer
• Rick D Anderson,
  Director
• Sciences Ii L P Pinto Techn...,
  
• Clercq Casper L. De,
  Director
• Sciences Ii L P Pinto Techn...,
  
• Perkins Caufield & Byers Xi...,
  
• James Stambaugh,
  VP, Clinical and Reimbursement
• Chas Mc Khann,
  Chief Commercial Officer
• Mark J Fletcher,
  Director
• Management Group Ix, L.L.C....,
  
• Venture Partners Xi, Lp Nor...,
  
• W Anthony Vernon,
  
• Reyna M Fernandez,
  Chief Human Resource Officer
• Patrick A Broderick,
  EVP, GC & Corporate Secretary
• Elisabeth Sandoval,